2-Methoxyestradiol interferes with NFκB transcriptional activity in primitive neuroectodermal brain tumors: Implications for management

Carcinogenesis

Volumn 24, Issue 2, 2003, Pages 209-216

  Kumar, Addanki P ^b   Garcia, Gretchen E ^b   Orsborn, Jon ^b   Levin, Victor A ^a   Slaga, Thomas J ^b  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF COLORADO CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHOXYESTRADIOL; ANTIMITOTIC AGENT; ANTINEOPLASTIC AGENT; BETA ACTIN; CARBOPLATIN; CASPASE; CHLORMETHINE; CISPLATIN; CYCLIN B1; CYCLIN DEPENDENT KINASE; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DNA FRAGMENT; ETOPOSIDE; GENOMIC DNA; IFOSFAMIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LOMUSTINE; MELPHALAN; METHOTREXATE; MITOLACTOL; PROCARBAZINE; PROTEIN 14 3 3; PROTEIN BAX; PROTEIN KINASE; PROTEIN P53; PROTEIN TYROSINE PHOSPHATASE; TRANSCRIPTION FACTOR; UNINDEXED DRUG; VINCRISTINE;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER RISK; CELL CYCLE; CELL CYCLE G2 PHASE; CONTROLLED STUDY; DNA BINDING; GLIOBLASTOMA; HUMAN; HUMAN CELL; MEDULLOBLASTOMA; NEUROECTODERM TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; TREATMENT INDICATION; TREATMENT OUTCOME; TUMOR CELL LINE; TUMOR GROWTH; TUMOR RECURRENCE;

APOPTOSIS; BRAIN NEOPLASMS; CELL DIVISION; ESTRADIOL; HUMANS; MEDULLOBLASTOMA; NF-KAPPA B; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED;

EID: 0037330674     PISSN: 01433334     EISSN: None     Source Type: Journal    
DOI: 10.1093/carcin/24.2.209     Document Type: Article

References (45)

1. Grill,J., Renaux,V.K., Bulteau,C., Viguier,D., Levy-Piebois,C., Sainte-Rose,C., Dellatolas,G., Raquin,M.A., Jambaque,I. and Kalifa,C. (1999). Long-term intellectual outcome in children with posterior fossa tumors according to radiation doses and volumes. Int. J. Radiat. Oncol. Biol. Phys., 45, 137-145.
2. Levin,V.A. (2000) Neuro-oncology-an overview [Review]. Arch. Neurol., 56, 401-404.
3. Levin,V.A., Leibel,S.A. and Gutin,P.H. (2001) Neoplasms of the central nervous system. In DeVita,V.T.J., Hellman,S. and Rosenberg,S.A. (eds), Cancer: Principles and Practice of Oncology. Lippincott-Raven, Philadelphia, pp. 2100-2160.
4. Mulhern,R.K., Palmer,S.L., Reddick,W.E., Glass,J.O., Kun,L.E., Taylor,J., Langston,J. and Gajjar,A. (2001). Risks of young age for selected neurocognitive deficits in medulloblastoma are associated with white matter loss. J. Clin. Oncol., 19, 472-479.
5. Mulhern,R.K., Reddick,W.E., Palmer,S.L., Glass,J.O., Elkin,T.D., Kun,L.E., Taylor,J., Langston,J. and Gajjar,A. (1999) Neurocognitive deficits in medulloblastoma survivors and white matter loss. Ann. Neurol., 46, 834-841.
6. Packer,R.J., Boyett,J.M., Janss,A.J. et al. (2001). Growth hormone replacement therapy in children with medulloblastoma: use and effect on tumor control. J. Clin. Oncol., 19, 480-487.
7. Palmer,S.L., Goloubeva,O., Reddick,W.E., Glass,J.O., Gajjar,A., Kun,L., Merchant,T.E. and Mulhern,R.K. (2001). Patterns of intellectual development among survivors of pediatric medulloblastoma: a longitudinal analysis. J. Clin. Oncol., 19, 2302-2308.
8. Pollack,I.F. (1999) Pediatric brain tumors. Semin. Surg. Oncol., 16, 73-90.
9. Goldwein,J.W., Radcliffe,J., Johnson,J., Moshang,T., Packer,R.J., Sutton,L.N., Roeke,L.B. and D'Angio,G.J. (1996). Updated results of a pilot study of low dose craniospinal irradiation plus chemotherapy for children under five with cerebellar primitive neuroectodermal tumors (medulloblastoma). Int. J. Radiat. Oncol. Biol. Phys., 34, 899-904.
10. Packer,R.J. (1999) Childhood medulloblastoma: progress and future challenges. Brain Dev., 21, 75-81.
11. Packer,R.J., Goldwein,J., Nicholson,H.S. et al. (1999) Treatment of children with medulloblastomas with reduced-dose craniospinal radiation therapy and adjuvant chemotherapy: A children's cancer group study. J. Clin. Oncol., 17, 2127-2136.
12. Zhu,B.T. and Conney,A.H. (1998) Is 2-methoxyestradiol an endogenous estrogen metabolite that inhibits mammary carcinogenesis. Cancer Res., 58, 2269-2277.
13. Schumacher,G., Kataoka,M., Roth,J.A. and Mukhopadhyay,T. (1999) Potent antitumor activity of 2-methoxyestradiol in human pancreatic cancer cell lines. Clin. Cancer Res., 5, 493-499.
14. 2/M phase and inhibits growth of human prostate cancer cells. Mol. Carcinogen., 31, 111-124.
15. Fotsis,T., Zhang,Y., Pepper,M.S., Adlercreutz,H., Montesano,R., Nawroth,P.P. and Schweigerer,O.L. (1994) The endogenous oestrogen metabolite 2-methoxyestradiol inhibits angiogenesis and suppresses tumor growth. Nature, 368, 237-239.
16. Krishan,A. (1975) Rapid flow cytofluorometric analysis of mammalian cell cycle by propidium iodide staining. J. Cell Biol., 66, 188-193.
17. Bradford,M.M. (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein dye binding. Anal. Biochem., 72, 248-254.
18. Kumar,A.P., Mar,P.K., Zhao,B., Montgomery,R.,L., Kang,D.-C. and Butler,A.P. (1995) Regulation of rat ornithine decarboxylase promoter activity by binding of transcription factor Sp1. J. Biol. Chem., 270, 4341-4348.
19. Laemmli,U.K. (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature, 227, 680-685.
20. Zamai,L., Falcieri,E., Zauli,G., Cataldi,A. and Vitale,M. (1993) Optimal detection of apoptosis by flow cytomtery depends on cell morphology. Cytometry, 14, 891-897.
21. Kerr,J.F.R. and Harmon,B.V. (1991) Apoptosis: The Molecular Basis of Cell Death. Cold Spring Harbor Laboratory Press, New York.
22. Wyllie,A.H. (1980) Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation. Nature, 284, 555-556.
23. Thornbery,N.A. (1999) Caspases: a decade of death research. Cell Death Diff., 6, 1023-1027.
24. Kaelin,W.G. (1999) The emerging p53 family. J. Natl Cancer Inst., 91, 594-598.
25. El-Deiry,W.S. (1998) Regulation of p53 downstream genes. Semin. Cancer Biol., 8, 345-357.
26. Jost,C., Marin,M. and Kaelin,W.G. (1997) p73 is a human p53-related protein that can induce apoptosis. Nature, 389, 191-194.
27. Yang,A., Kaghad,M., Wang,Y. et al. (1998) p63, a p53-related protein, p73L, with high homology to p73. Biochem. Biophys. Res. Commun., 248, 603-607.
28. Ghosh,R., Ott,A.M., Seetharam,D., Slaga,T.J. and Kumar,A.P. (2003) Cell cycle block and apoptosis induction in a human melanoma cell line following treatment with 2-methoxyestradiol: therapeutic implications? Melanoma Res., (in press).
29. Hoffmann,I.C., Marcote,P.R., Karsenti,E., Draetta,G. (1993) Phosphorylation and activation of human cdc25-C by cdc2-cyclin B and its involvement in the self-amplification of MPF at mitosis. EMBO J., 12, 53-6393.
30. Nurse,P. (1990) Universal control mechanism regulating onset of M phase. Nature, 344, 503-508.
31. Tzivion,G., Shen,Y.H. and Zhu,J. (2001) 14-3-3 proteins; bringing new definitions to scaffolding. Oncogene, 20, 6331-6338.
32. 2/M transition. Biochim. Biophys. Acta, 1519, 1-12.
33. Ryan,K.M., Ernst,M.E., Rice,N.R. and Vousden,K.H. (2000) Role of NFκB in p53-mediated programmed cell death. Nature, 404, 892-896.
34. Wang,C.Y., Mayo,M.W., Korneluk,R.G., Goeddel,D.V. and Baldwin,A.S. Jr (1998) NFκB antiapoptosis: induction of TRAF1 and TRAF2 and C-IAP1 and C-IAP2 to suppress caspase 8 activation. Science, 281, 1680-1683.
35. Beg,A.A., Sha,W.C., Bronson,R.T., Ghosh,S. and Baltimore,D. (1995) Embryonic lethality and liver degeneration in mice lacking the RelA component of NFκB. Nature, 376, 167-170.
36. Liu,Z.-G., Hsu,H., Goeddel,D.V. and Karin,M. (1996) Dissection of TNF receptor I effector functions: JNK activation is not linked to apoptosis while NFκB activation prevents cells death. Cell, 87, 565-576.
37. Jenkin,D., Shabanah,M.A., Shail,E.A., Gray,A., Hassounah,M., Khafaga,Y., Kofide,A., Mustafa,M. and Schultz,H. (2000) Prognostic factors for medulloblastoma. Int. J. Radiat. Oncol. Biol. Phys., 47, 573-584.
38. Kieffer-Renaux,V., Bulteau,C., Grill,J., Kalifa,C., Viguier,D. and Jambaque,I. (2000) Patterns of neuropsychological deficits in children with medulloblastoma according to craniospatial irradiation doses. In Dev. Med. Child Neurol., Cambridge University Press, New York, SN-0012-1622, 42, 741-745.
39. Berg,F.D. and Kuss,E. (1992) Serum concentrations and urinary excretion of classical estrogens, catecholestrogens and 2-methoxyestrogens in normal human pregnancy. Arch. Gynecol Obstet., 251, 17-27.
40. Pribluda,V.S., Gubih,E.R., La Vallee,T.M., Treston,A., Swartz,G.M. and Green,S.J. (2000) 2-Methoxyestradiol: an endogenous antiangiogenic and antiproliferative drug candidate. Cancer Metastasis Rev., 19, 173-179.
41. Schumacher,G. and Neuhaus,P. (2001) The physiological estrogen metabolite 2-methoxyestradiol reduces tumor growth and induces apoptosis in human solid tumors. J. Cancer Res. Clin. Oncol., 127, 405-410.
42. Lottering,M.L., Haag,M. and Seegers,J.C. (1992) Effects of 17 β-estradiol metabolites on cell cycle events in MCF-7 cells. Cancer Res., 52, 5926-5932.
43. Mukhopadhyay,T. and Roth,J. (1997) A. Induction of apoptosis in human lung cancer cells after wild type p53 activation by methoxyestradiol. Oncogene, 14, 379-384.
44. Seeger,J.C., Lottering,M.-C., Grobler,C.J., van Papendorp,D.H., Habbersett,R.C., Shou,Y. and Lehnert,B.E. (1997) The mammalian metabolite 2-methoxyestradiol alters p53 levels and apoptosis induction in transformed cells. J. Steroid Biochem. Mol. Biol., 62, 253-267.
45. Mukhopadhyay,T. and Roth,J.A. (1998) Super induction of wild type p53 protein after 2-methoxyestradiol treatment of Ad5p53-transduced cells induce tumor cell apoptosis. Oncogene, 17, 241-246.